150 related articles for article (PubMed ID: 29332581)
21. Open-label, uncontrolled, multicenter phase II study to evaluate the efficacy and toxicity of cetuximab as a single agent in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck who failed to respond to platinum-based therapy.
Vermorken JB; Trigo J; Hitt R; Koralewski P; Diaz-Rubio E; Rolland F; Knecht R; Amellal N; Schueler A; Baselga J
J Clin Oncol; 2007 Jun; 25(16):2171-7. PubMed ID: 17538161
[TBL] [Abstract][Full Text] [Related]
22. Expanding the Reach of Anti-PD-1 Therapy.
Cancer Discov; 2015 Jul; 5(7):684-5. PubMed ID: 26034052
[TBL] [Abstract][Full Text] [Related]
23. Cetuximab promotes epithelial to mesenchymal transition and cancer associated fibroblasts in patients with head and neck cancer.
Schmitz S; Bindea G; Albu RI; Mlecnik B; Machiels JP
Oncotarget; 2015 Oct; 6(33):34288-99. PubMed ID: 26437222
[TBL] [Abstract][Full Text] [Related]
24. Treatment of unresectable squamous cell carcinoma of the skin with epidermal growth factor receptor antibodies--a case series.
Eder J; Simonitsch-Klupp I; Trautinger F
Eur J Dermatol; 2013; 23(5):658-62. PubMed ID: 24135559
[TBL] [Abstract][Full Text] [Related]
25. Intra-tumor AvidinOX allows efficacy of low dose systemic biotinylated Cetuximab in a model of head and neck cancer.
Vesci L; Milazzo FM; Anastasi AM; Petronzelli F; Chiapparino C; Carollo V; Roscilli G; Marra E; Luberto L; Aurisicchio L; Pacello ML; Spagnoli LG; De Santis R
Oncotarget; 2016 Jan; 7(1):914-28. PubMed ID: 26575422
[TBL] [Abstract][Full Text] [Related]
26. Drug Insight: cetuximab in the treatment of recurrent and metastatic squamous cell carcinoma of the head and neck.
Bernier J
Nat Clin Pract Oncol; 2008 Dec; 5(12):705-13. PubMed ID: 18825142
[TBL] [Abstract][Full Text] [Related]
27. Genistein as a Potential Anticancer Agent Against Head and Neck Squamous Cell Carcinoma.
Ardito F; Di Gioia G; Pellegrino MR; Muzio LL
Curr Top Med Chem; 2018; 18(3):174-181. PubMed ID: 29345579
[TBL] [Abstract][Full Text] [Related]
28. Pharmacotherapy of head and neck squamous cell carcinoma.
Pan Q; Gorin MA; Teknos TN
Expert Opin Pharmacother; 2009 Oct; 10(14):2291-302. PubMed ID: 19663637
[TBL] [Abstract][Full Text] [Related]
29. Autophagic action of new targeting agents in head and neck oncology.
Rikiishi H
Cancer Biol Ther; 2012 Sep; 13(11):978-91. PubMed ID: 22825332
[TBL] [Abstract][Full Text] [Related]
30. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma.
Chung CH; Pohlmann PR; Rothenberg ML; Burkey BB; Parker J; Palka K; Aulino J; Puzanov I; Murphy B
Head Neck; 2011 Dec; 33(12):1804-8. PubMed ID: 20652976
[TBL] [Abstract][Full Text] [Related]
31. EpCAM and EGFR crosstalk in the development of resistance towards Cetuximab treatment in head and neck cancer.
He M; Gouda M; Gires O
Oral Oncol; 2023 Aug; 143():106465. PubMed ID: 37348447
[No Abstract] [Full Text] [Related]
32. Target therapies in recurrent or metastatic head and neck cancer: state of the art and novel perspectives. A systematic review.
Muratori L; La Salvia A; Sperone P; Di Maio M
Crit Rev Oncol Hematol; 2019 Jul; 139():41-52. PubMed ID: 31112881
[TBL] [Abstract][Full Text] [Related]
33. Role of Immunotherapy in Head and Neck Cancer.
Ling DC; Bakkenist CJ; Ferris RL; Clump DA
Semin Radiat Oncol; 2018 Jan; 28(1):12-16. PubMed ID: 29173750
[TBL] [Abstract][Full Text] [Related]
34. Eating Green: Shining Light on the Use of Dietary Phytochemicals as a Modern Approach in the Prevention and Treatment of Head and Neck Cancers.
Eastham LL; Howard CM; Balachandran P; Pasco DS; Claudio PP
Curr Top Med Chem; 2018; 18(3):182-191. PubMed ID: 29332583
[TBL] [Abstract][Full Text] [Related]
35. [Vitamin D in relation to head and neck cancer].
Kalfeřt D; Ludvíková M; Pešta M; Topolčan O
Vnitr Lek; 2014 Jan; 60(1):51-8. PubMed ID: 24564776
[TBL] [Abstract][Full Text] [Related]
36. Call for Adoption of Synchronized Biweekly Dosing of Anti-EGFR Agent Cetuximab: Implications for Patients with Metastatic Colorectal Cancer, and Squamous Cell Carcinoma of the Head and Neck.
Kasi PM
Oncologist; 2022 May; 27(5):336-337. PubMed ID: 35403691
[TBL] [Abstract][Full Text] [Related]
37. Searching for New Targets and Treatments in the Battle Against Squamous Cell Carcinoma of the Head and Neck, with Specific Focus on Tumours of the Tongue.
Sgaramella N; Gu X; Boldrup L; Coates PJ; Fahraeus R; Califano L; Tartaro G; Colella G; Spaak LN; Strom A; Wilms T; Muzio LL; Orabona GD; Santagata M; Loljung L; Rossiello R; Danielsson K; Strindlund K; Lillqvist S; Nylander K
Curr Top Med Chem; 2018; 18(3):214-218. PubMed ID: 29345578
[TBL] [Abstract][Full Text] [Related]
38. Matrisomal genes in squamous cell carcinoma of head and neck influence tumor cell motility and response to cetuximab treatment.
Goh KY; Lau KW; Cheng TY; Tham SC; Lim CT; Iyer NG; Lim SB; Lim DW
Cancer Commun (Lond); 2022 Apr; 42(4):355-359. PubMed ID: 35234368
[No Abstract] [Full Text] [Related]
39. Severe Pain Due to Paraspinal Abscess Formation in Two Patients with Squamous-Cell Carcinoma of the Head and Neck after Multimodal Treatment Including Cetuximab.
Gerlach C; Pretzell I; Lieberknecht E; Mattyasovszky S; Weber M
Oncol Res Treat; 2018; 41(6):395-398. PubMed ID: 29734190
[TBL] [Abstract][Full Text] [Related]
40. Metabolic Imaging of Head and Neck Cancer Organoids.
Shah AT; Heaster TM; Skala MC
PLoS One; 2017; 12(1):e0170415. PubMed ID: 28099487
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
